Hepatitis A vaccine failure: how to treat the threat
[...]a seroconversion rate of 98.1% has been observed in one "in the field" vaccination trial (Mele, unpublished observations). [...]a small proportion of non-responders may exist. [4] indicate that vaccination may not be synonymous to protection. Since travellers to endemic countries are...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2003-11, Vol.21 (31), p.4505-4506 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4506 |
|---|---|
| container_issue | 31 |
| container_start_page | 4505 |
| container_title | Vaccine |
| container_volume | 21 |
| creator | Taliani, Gloria Sbaragli, Serena Bartoloni, Alessandro Santini, Maria Grazia Tozzi, Alessandro Paradisi, Franco |
| description | [...]a seroconversion rate of 98.1% has been observed in one "in the field" vaccination trial (Mele, unpublished observations). [...]a small proportion of non-responders may exist. [4] indicate that vaccination may not be synonymous to protection. Since travellers to endemic countries are exposed to the most significant risk of HAV infection and they often seek medical advice before leaving, correct counselling consisting in the recommendation of continuous adherence to the universal safety measures for the prevention of faecal-oral infections should be strongly advised. |
| doi_str_mv | 10.1016/S0264-410X(03)00502-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1546776516</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X03005024</els_id><sourcerecordid>3379154911</sourcerecordid><originalsourceid>FETCH-LOGICAL-c358t-b94bb3addf255941ac15405ae941d5f30f75ca68e7342326b768c15e461045b43</originalsourceid><addsrcrecordid>eNqFkE1LAzEQhoMotlZ_grLgRQ-ryeZr14uUolYoeFDBW8hmZ2lK261JtuK_N9suepQwZA7PvMM8CJ0TfEMwEbevOBMsZQR_XGF6jTHHWcoO0JDkkqYZJ_khGv4iA3Ti_QJHipLiGA0I4zK-YojYFDY62GB9Mk622hi7hqTWdtk6uEvmzVcSmiQ40CEJc4jVtafoqNZLD2f9P0Lvjw9vk2k6e3l6noxnqaE8D2lZsLKkuqrqjPOCEW0IZ5hriH3Fa4pryY0WOUjKMpqJUoo8IsAEwYyXjI7Q5T5345rPFnxQi6Z167hSxSQhpeBERIrvKeMa7x3UauPsSrtvRbDqXKmdK9WJUJiqnSvVpV_06W25gupvqpcTgfs9APHGrQWnvLGwNlBZByaoqrH_rPgBO352bw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1546776516</pqid></control><display><type>article</type><title>Hepatitis A vaccine failure: how to treat the threat</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Taliani, Gloria ; Sbaragli, Serena ; Bartoloni, Alessandro ; Santini, Maria Grazia ; Tozzi, Alessandro ; Paradisi, Franco</creator><creatorcontrib>Taliani, Gloria ; Sbaragli, Serena ; Bartoloni, Alessandro ; Santini, Maria Grazia ; Tozzi, Alessandro ; Paradisi, Franco</creatorcontrib><description>[...]a seroconversion rate of 98.1% has been observed in one "in the field" vaccination trial (Mele, unpublished observations). [...]a small proportion of non-responders may exist. [4] indicate that vaccination may not be synonymous to protection. Since travellers to endemic countries are exposed to the most significant risk of HAV infection and they often seek medical advice before leaving, correct counselling consisting in the recommendation of continuous adherence to the universal safety measures for the prevention of faecal-oral infections should be strongly advised.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/S0264-410X(03)00502-4</identifier><identifier>PMID: 14575759</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adult ; Cytomegalovirus ; Developing countries ; Eritrea ; Hepatitis A - epidemiology ; Hepatitis A - prevention & control ; Hepatitis A Vaccines - immunology ; Humans ; Immunization ; India ; Infections ; Italy - epidemiology ; LDCs ; Male ; Treatment Failure ; Tuberculosis ; Vaccines</subject><ispartof>Vaccine, 2003-11, Vol.21 (31), p.4505-4506</ispartof><rights>2003 Elsevier Science Ltd</rights><rights>Copyright Elsevier Limited Nov 7, 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c358t-b94bb3addf255941ac15405ae941d5f30f75ca68e7342326b768c15e461045b43</citedby><cites>FETCH-LOGICAL-c358t-b94bb3addf255941ac15405ae941d5f30f75ca68e7342326b768c15e461045b43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X03005024$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14575759$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Taliani, Gloria</creatorcontrib><creatorcontrib>Sbaragli, Serena</creatorcontrib><creatorcontrib>Bartoloni, Alessandro</creatorcontrib><creatorcontrib>Santini, Maria Grazia</creatorcontrib><creatorcontrib>Tozzi, Alessandro</creatorcontrib><creatorcontrib>Paradisi, Franco</creatorcontrib><title>Hepatitis A vaccine failure: how to treat the threat</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>[...]a seroconversion rate of 98.1% has been observed in one "in the field" vaccination trial (Mele, unpublished observations). [...]a small proportion of non-responders may exist. [4] indicate that vaccination may not be synonymous to protection. Since travellers to endemic countries are exposed to the most significant risk of HAV infection and they often seek medical advice before leaving, correct counselling consisting in the recommendation of continuous adherence to the universal safety measures for the prevention of faecal-oral infections should be strongly advised.</description><subject>Adult</subject><subject>Cytomegalovirus</subject><subject>Developing countries</subject><subject>Eritrea</subject><subject>Hepatitis A - epidemiology</subject><subject>Hepatitis A - prevention & control</subject><subject>Hepatitis A Vaccines - immunology</subject><subject>Humans</subject><subject>Immunization</subject><subject>India</subject><subject>Infections</subject><subject>Italy - epidemiology</subject><subject>LDCs</subject><subject>Male</subject><subject>Treatment Failure</subject><subject>Tuberculosis</subject><subject>Vaccines</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkE1LAzEQhoMotlZ_grLgRQ-ryeZr14uUolYoeFDBW8hmZ2lK261JtuK_N9suepQwZA7PvMM8CJ0TfEMwEbevOBMsZQR_XGF6jTHHWcoO0JDkkqYZJ_khGv4iA3Ti_QJHipLiGA0I4zK-YojYFDY62GB9Mk622hi7hqTWdtk6uEvmzVcSmiQ40CEJc4jVtafoqNZLD2f9P0Lvjw9vk2k6e3l6noxnqaE8D2lZsLKkuqrqjPOCEW0IZ5hriH3Fa4pryY0WOUjKMpqJUoo8IsAEwYyXjI7Q5T5345rPFnxQi6Z167hSxSQhpeBERIrvKeMa7x3UauPsSrtvRbDqXKmdK9WJUJiqnSvVpV_06W25gupvqpcTgfs9APHGrQWnvLGwNlBZByaoqrH_rPgBO352bw</recordid><startdate>20031107</startdate><enddate>20031107</enddate><creator>Taliani, Gloria</creator><creator>Sbaragli, Serena</creator><creator>Bartoloni, Alessandro</creator><creator>Santini, Maria Grazia</creator><creator>Tozzi, Alessandro</creator><creator>Paradisi, Franco</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope></search><sort><creationdate>20031107</creationdate><title>Hepatitis A vaccine failure: how to treat the threat</title><author>Taliani, Gloria ; Sbaragli, Serena ; Bartoloni, Alessandro ; Santini, Maria Grazia ; Tozzi, Alessandro ; Paradisi, Franco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c358t-b94bb3addf255941ac15405ae941d5f30f75ca68e7342326b768c15e461045b43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Cytomegalovirus</topic><topic>Developing countries</topic><topic>Eritrea</topic><topic>Hepatitis A - epidemiology</topic><topic>Hepatitis A - prevention & control</topic><topic>Hepatitis A Vaccines - immunology</topic><topic>Humans</topic><topic>Immunization</topic><topic>India</topic><topic>Infections</topic><topic>Italy - epidemiology</topic><topic>LDCs</topic><topic>Male</topic><topic>Treatment Failure</topic><topic>Tuberculosis</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Taliani, Gloria</creatorcontrib><creatorcontrib>Sbaragli, Serena</creatorcontrib><creatorcontrib>Bartoloni, Alessandro</creatorcontrib><creatorcontrib>Santini, Maria Grazia</creatorcontrib><creatorcontrib>Tozzi, Alessandro</creatorcontrib><creatorcontrib>Paradisi, Franco</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Taliani, Gloria</au><au>Sbaragli, Serena</au><au>Bartoloni, Alessandro</au><au>Santini, Maria Grazia</au><au>Tozzi, Alessandro</au><au>Paradisi, Franco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hepatitis A vaccine failure: how to treat the threat</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2003-11-07</date><risdate>2003</risdate><volume>21</volume><issue>31</issue><spage>4505</spage><epage>4506</epage><pages>4505-4506</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>[...]a seroconversion rate of 98.1% has been observed in one "in the field" vaccination trial (Mele, unpublished observations). [...]a small proportion of non-responders may exist. [4] indicate that vaccination may not be synonymous to protection. Since travellers to endemic countries are exposed to the most significant risk of HAV infection and they often seek medical advice before leaving, correct counselling consisting in the recommendation of continuous adherence to the universal safety measures for the prevention of faecal-oral infections should be strongly advised.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>14575759</pmid><doi>10.1016/S0264-410X(03)00502-4</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2003-11, Vol.21 (31), p.4505-4506 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_journals_1546776516 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adult Cytomegalovirus Developing countries Eritrea Hepatitis A - epidemiology Hepatitis A - prevention & control Hepatitis A Vaccines - immunology Humans Immunization India Infections Italy - epidemiology LDCs Male Treatment Failure Tuberculosis Vaccines |
| title | Hepatitis A vaccine failure: how to treat the threat |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T20%3A46%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hepatitis%20A%20vaccine%20failure:%20how%20to%20treat%20the%20threat&rft.jtitle=Vaccine&rft.au=Taliani,%20Gloria&rft.date=2003-11-07&rft.volume=21&rft.issue=31&rft.spage=4505&rft.epage=4506&rft.pages=4505-4506&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/S0264-410X(03)00502-4&rft_dat=%3Cproquest_cross%3E3379154911%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1546776516&rft_id=info:pmid/14575759&rft_els_id=S0264410X03005024&rfr_iscdi=true |